Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07367971 · ClinicalTrials.gov registry record · Phase 1
Drug-Drug Interaction Study of ABP-671 in Gout Patients
A Phase 1 study, sponsored by Atom Therapeutics Co..
- Recruiting
- Registry status
- Phase 1
- Development phase
- 20
- Enrollment target
NCT07367971 is a Phase 1 study that is actively recruiting participants, run by Atom Therapeutics Co.. The registered enrollment target is 20 participants.
The verdict
NCT07367971, a Phase 1 study, is actively recruiting participants, sponsored by Atom Therapeutics Co..
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 20 participants
- Enrollment target
Study Summary
This is a open-Label, Within-Subject Drug-Drug Interaction Study of ABP-671 Added to Stable Allopurinol Therapy in Gout Patients. Pharmacokinetic (PK) interaction between ABP-671 and Allopurinol will be evaluated in participants who are on stable Allopurinol therapy.
Interventions
- DRUG ABP-671 plus allopurinol
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 20 participants |
| Start Date | 2026-01-23 |
| Est. Completion | 2026-08-31 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT07367971
The ClinicalTrials.gov registry entry for NCT07367971 describes a study currently listed as recruiting, categorized as Phase 1. The registered enrollment target is 20 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Atom Therapeutics Co., which has 9 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which ABP-671 plus allopurinol is the first listed.
NCT07367971 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT07367971 about?
NCT07367971 is a clinical study titled "Drug-Drug Interaction Study of ABP-671 in Gout Patients". This is a open-Label, Within-Subject Drug-Drug Interaction Study of ABP-671 Added to Stable Allopurinol Therapy in Gout Patients. Pharmacokinetic (PK) interaction between ABP-671 and Allopurinol will be evaluated in participants who are on stable Allopurinol therapy.
What is the current status of trial NCT07367971?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 20 participants. The study started on 2026-01-23. Estimated completion is 2026-08-31.
What interventions are being tested in trial NCT07367971?
The interventions under investigation include: ABP-671 plus allopurinol (DRUG).
Who is sponsoring clinical trial NCT07367971?
This trial is sponsored by Atom Therapeutics Co., which has 9 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.